In humans, ANXA2 has been identified as a poor prognostic factor for endometrial cancer37, estrogen receptor negative (ER-) breast cancer and its subtypes38, while it promotes endometrial cells' proangiogenic capacity39. Here, ESR1 is linked to breast carcinoma.